Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis.

Published in: Journal of medical economics (2022)

Levalbuterol is a cost-saving option for treating hospitalized patients with COPD in China.

Keyphrases